Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia

• Published in: Antimicrobial agents and chemotherapy Vol. 58; no. 12; pp. 7072 - 7082
• Main Authors: Reyes-Vivas, Horacio, de la Mora-de la Mora, Ignacio, Castillo-Villanueva, Adriana, Yépez-Mulia, Lilian, Hernández-Alcántara, Gloria, Figueroa-Salazar, Rosalia, García-Torres, Itzhel, Gómez-Manzo, Saúl, Méndez, Sara T, Vanoye-Carlo, América, Marcial-Quino, Jaime, Torres-Arroyo, Angélica, Oria-Hernández, Jesús, Gutiérrez-Castrellón, Pedro, Enríquez-Flores, Sergio, López-Velázquez, Gabriel
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.12.2014
• Subjects: Albendazole - pharmacology; Antiprotozoal Agents; Antiprotozoal Agents - pharmacology; Axenic Culture; Cysteine - chemistry; Cysteine - metabolism; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Inhibitors; Enzyme Inhibitors - pharmacology; Escherichia coli - genetics; Escherichia coli - metabolism; Gene Expression; Giardia lamblia; Giardia lamblia - drug effects; Giardia lamblia - enzymology; Giardia lamblia - growth & development; Giardia lamblia - isolation & purification; Humans; Mechanisms of Action: Physiological Effects; Metronidazole - pharmacology; Mutation; Omeprazole; Omeprazole - pharmacology; Parasitic Sensitivity Tests; Protozoan Proteins; Protozoan Proteins - antagonists & inhibitors; Protozoan Proteins - genetics; Protozoan Proteins - metabolism; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; Spectrometry, Fluorescence; Thiazoles - pharmacology; Triose-Phosphate Isomerase; Triose-Phosphate Isomerase - antagonists & inhibitors; Triose-Phosphate Isomerase - genetics; Triose-Phosphate Isomerase - metabolism; Trophozoites; Trophozoites - drug effects; Trophozoites - enzymology; Trophozoites - growth & development
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.02900-14

Giardiasis is highly prevalent in the developing world, and treatment failures with the standard drugs are common. This work deals with the proposal of omeprazole as a novel antigiardial drug, focusing on a giardial glycolytic enzyme used to follow the cytotoxic effect at the molecular level. We used recombinant technology and enzyme inactivation to demonstrate the capacity of omeprazole to inactivate giardial triosephosphate isomerase, with no adverse effects on its human counterpart. To establish the specific target in the enzyme, we used single mutants of every cysteine residue in triosephosphate isomerase. The effect on cellular triosephosphate isomerase was evaluated by following the remnant enzyme activity on trophozoites treated with omeprazole. The interaction of omeprazole with giardial proteins was analyzed by fluorescence spectroscopy. The susceptibility to omeprazole of drug-susceptible and drug-resistant strains of Giardia lamblia was evaluated to demonstrate its potential as a novel antigiardial drug. Our results demonstrate that omeprazole inhibits giardial triosephosphate isomerase in a species-specific manner through interaction with cysteine at position 222. Omeprazole enters the cytoplasmic compartment of the trophozoites and inhibits cellular triosephosphate isomerase activity in a dose-dependent manner. Such inhibition takes place concomitantly with the cytotoxic effect caused by omeprazole on trophozoites. G. lamblia triosephosphate isomerase (GlTIM) is a cytoplasmic protein which can help analyses of how omeprazole works against the proteins of this parasite and in the effort to understand its mechanism of cytotoxicity. Our results demonstrate the mechanism of giardial triosephosphate isomerase inhibition by omeprazole and show that this drug is effective in vitro against drug-resistant and drug-susceptible strains of G. lamblia.